[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Burlot et al., 2015 - Google Patents

Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology

Burlot et al., 2015

View HTML
Document ID
9714025733966448012
Author
Burlot M
Braudeau J
Michaelsen-Preusse K
Potier B
Ayciriex S
Varin J
Gautier B
Djelti F
Audrain M
Dauphinot L
Fernandez-Gomez F
Caillierez R
Laprévote O
Bieche I
Auzeil N
Potier M
Dutar P
Korte M
Buée L
Blum D
Cartier N
Publication year
Publication venue
Human molecular genetics

External Links

Snippet

Alzheimer's disease (AD) is characterized by both amyloid and Tau pathologies. The amyloid component and altered cholesterol metabolism are closely linked, but the relationship between Tau pathology and cholesterol is currently unclear. Brain cholesterol is …
Continue reading at academic.oup.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids

Similar Documents

Publication Publication Date Title
Burlot et al. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology
Findley et al. Amyloid beta-related alterations to glutamate signaling dynamics during Alzheimer’s disease progression
Rockenstein et al. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo
Bassil et al. α-Synuclein modulates tau spreading in mouse brains
Kapeli et al. Genetic mutations in RNA-binding proteins and their roles in ALS
Teravskis et al. A53T mutant alpha-synuclein induces tau-dependent postsynaptic impairment independently of neurodegenerative changes
O’Hara et al. LRRK2 and α-synuclein: distinct or synergistic players in Parkinson’s disease?
Kabashi et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo
Vanderweyde et al. Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies
Xu et al. Dysregulation of Rab5‐mediated endocytic pathways in Alzheimer's disease
Sekiguchi et al. A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice
Hunn et al. Impaired intracellular trafficking defines early Parkinson's disease
Chen et al. The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis
Gottschalk et al. The broad impact of TOM40 on neurodegenerative diseases in aging
Parra-Damas et al. Crtc1 activates a transcriptional program deregulated at early Alzheimer's disease-related stages
Mihaylova et al. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes
Abdulkarim et al. A missense mutation in PPP1R15B causes a syndrome including diabetes, short stature, and microcephaly
Cheng et al. α‐Synuclein promotes clathrin‐mediated NMDA receptor endocytosis and attenuates NMDA‐induced dopaminergic cell death
Hantke et al. c-Jun activation in Schwann cells protects against loss of sensory axons in inherited neuropathy
Emanuele et al. Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role
Liu et al. β-arrestin1 regulates γ-secretase complex assembly and modulates amyloid-β pathology
Giavazzi et al. Neuronal-specific roles of the survival motor neuron protein: evidence from survival motor neuron expression patterns in the developing human central nervous system
Nakata et al. Accumulation of α-synuclein triggered by presynaptic dysfunction
Bar‐On et al. Effects of the cholesterol‐lowering compound methyl‐β‐cyclodextrin in models of α‐synucleinopathy
Pacheco et al. Tau deletion exacerbates the phenotype of Niemann–Pick type C mice and implicates autophagy in pathogenesis